Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Hyperthermic Intraperitoneal Chemotherapy
100%
Cytoreductive Surgery
93%
Esophagectomy
53%
Carcinomatous Peritonitis
43%
Neoplasm
35%
Overall Survival
31%
Recurrent Disease
31%
Peritoneum Metastasis
23%
Peritoneum Cancer
19%
Morbidity
19%
Patient Selection
18%
Signet Ring Cell
17%
Surgeon
16%
Esophageal Adenocarcinoma
14%
Gallbladder Cancer
14%
Esophageal Cancer
14%
Cancer
14%
Lymph Node
14%
Neoadjuvant Therapy
13%
Esophagus Carcinoma
13%
Abdominal Cancer
12%
Long Term Survival
10%
Long-Term Outcome
10%
Colorectal Carcinoma
9%
Malignant Neoplasm
9%
Health System
9%
Quality of Life
8%
Peritoneal Disease
8%
Primary Tumor
8%
Adenocarcinoma
7%
Learning Curve
7%
Multivariate Analysis
7%
Arm
7%
Systematic Review
7%
Early Cancer Detection
7%
Tumor Regression
7%
Retroperitoneal Lymph Node Dissection
7%
Gastrectomy
7%
Chemoradiotherapy
7%
Thoracic Duct
7%
Distal Pancreatectomy
7%
Carcinosis
7%
Spiral Computed Tomography
7%
Hepatocellular Carcinoma
7%
Lung Cancer
7%
Anastomosis Leakage
7%
Cohort Analysis
7%
Hepatobiliary Cancer
7%
Diaphragm
7%
Esophagus Perforation
7%
Keyphrases
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
86%
Cytoreductive Surgery
67%
Peritoneal Carcinomatosis
34%
Esophagectomy
23%
Overall Survival
23%
Peritoneal Metastasis
22%
Resection
21%
Patient Selection
19%
Postoperative Outcomes
19%
Peritoneal Cancer Index
18%
Long-term Survival
17%
High-volume Center
17%
Signet Ring Cell
16%
Low-grade Appendiceal mucinous Neoplasm
15%
Esophageal Adenocarcinoma
14%
Gallbladder Cancer
14%
Esophageal Cancer
14%
Outcome Prediction
14%
Secondary Cytoreductive Surgery
12%
Neoadjuvant Therapy
12%
Appendiceal
11%
Minimally Invasive Esophagectomy
10%
Histology
9%
Esophageal Carcinoma
9%
Colorectal Cancer
9%
Adenocarcinoma
9%
Oncological Outcomes
9%
Peritoneal Disease
8%
Tertiary Care Centers
8%
95% Confidence Interval
8%
Primary Tumor
8%
Aged 80
8%
Gastrointestinal Malignancies
8%
After Esophagectomy
8%
Esophageal Resection
8%
Poor Response
7%
Patient Survival
7%
Surgical Management
7%
Very Old
7%
Outcome Selection
7%
Laparoscopic Cytoreductive Surgery
7%
Laparoscopic Distal Gastrectomy
7%
Distal Pancreatectomy
7%
Curative Surgical Resection
7%
Appendiceal Adenocarcinoma
7%
Older Adults
7%
Tumor Survival
7%
Learning Curve
7%
Lung Cancer Patients
7%
Pentraxin 3 (PTX3)
7%